新型选择性雌激素受体降解剂（SERDs）的药效团性质特征描述。
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).
机构信息
Department of Chemistry, University of Illinois, 600 South Mathews Avenue, Urbana, Illinois 61801, USA.
出版信息
J Med Chem. 2010 Apr 22;53(8):3320-9. doi: 10.1021/jm100047k.
Abstract
Selective estrogen receptor (ER) down-regulators (SERDs) reduce ERalpha protein levels as well as block ER activity and therefore are promising therapeutic agents for the treatment of hormone refractory breast cancer. Starting with the triarylethylene acrylic acid SERD 4, we have investigated how alterations in both the ligand core structure and the appended acrylic acid substituent affect SERD activity. The new ligands were based on high affinity, symmetrical cyclofenil or bicyclo[3.3.1]nonane core systems, and in these, the position of the carboxyl group was extended from the ligand core, either retaining the vinylic linkage of the substituent or replacing it with an ether linkage. Although most structural variants showed binding affinities for ERalpha and ERbeta higher than that of 4, only the compounds preserving the acrylic acid side chain retained SERD activity, although they could possess varying core structures. Hence, the acrylic acid moiety of the ligand is crucial for SERD-like blockade of ER activities.
摘要
选择性雌激素受体（ER）下调剂（SERD）降低 ERalpha 蛋白水平，并阻断 ER 活性，因此是治疗激素难治性乳腺癌的有前途的治疗剂。从三芳基乙烯丙烯酸 SERD 4 开始，我们研究了配体核心结构和附加的丙烯酸取代基的变化如何影响 SERD 活性。新的配体基于高亲和力的对称环己芬或双环[3.3.1]壬烷核心系统，在这些系统中，羧基的位置从配体核心延伸，保留取代基的乙烯基键或用醚键取代它。尽管大多数结构变体对 ERalpha 和 ERbeta 的结合亲和力高于 4，但只有保留丙烯酸侧链的化合物保留了 SERD 活性，尽管它们可以具有不同的核心结构。因此，配体的丙烯酸部分对于 ER 活性的 SERD 样阻断至关重要。
相似文献
1
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).新型选择性雌激素受体降解剂（SERDs）的药效团性质特征描述。
J Med Chem. 2010 Apr 22;53(8):3320-9. doi: 10.1021/jm100047k.
2
Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor.含有1,1-二芳基乙烯基序的桥连双环核心是雌激素受体的高亲和力亚型选择性配体。
J Med Chem. 2003 Apr 24;46(9):1589-602. doi: 10.1021/jm0204800.
3
Exploration of the bicyclo[3.3.1]nonane system as a template for the development of new ligands for the estrogen receptor.探索双环[3.3.1]壬烷体系作为开发雌激素受体新配体的模板。
Bioorg Med Chem Lett. 2003 Dec 15;13(24):4485-8. doi: 10.1016/j.bmcl.2003.08.061.
4
Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.新型选择性雌激素受体配体缀合物，结合了内消旋体依西美坦和金雀异黄素-桑色素杂合骨架：合成与生化评价。
Molecules. 2017 Aug 31;22(9):1440. doi: 10.3390/molecules22091440.
5
Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.二芳基乙烯基和环戊二烯基衍生的双雌激素受体拮抗剂和下调剂的开发。
Eur J Med Chem. 2020 Apr 15;192:112191. doi: 10.1016/j.ejmech.2020.112191. Epub 2020 Feb 28.
6
Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer.氟取代环芬尼衍生物作为雌激素受体配体：用于乳腺癌雌激素受体成像的潜在正电子发射断层显像剂的合成及结构-亲和力关系研究
J Med Chem. 2006 Apr 20;49(8):2496-511. doi: 10.1021/jm0512037.
7
A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).一种用于鉴定和表征新型选择性雌激素受体下调剂（SERD）的筛选分析级联。
J Biomol Screen. 2015 Jul;20(6):748-59. doi: 10.1177/1087057115580298. Epub 2015 Apr 7.
8
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.苯并[E]氧杂环庚烯类选择性雌激素受体（ER）调节剂和下调剂的先导优化，具有亚型特异性的 ERα 和 ERβ 活性。
J Med Chem. 2018 Jan 25;61(2):514-534. doi: 10.1021/acs.jmedchem.6b01917. Epub 2017 May 1.
9
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.具有二苯甲烷骨架的雌激素受体下调剂的构效关系研究。
Bioorg Med Chem. 2019 May 15;27(10):1952-1961. doi: 10.1016/j.bmc.2019.03.042. Epub 2019 Mar 26.
10
Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters.雌激素受体（ER）β通过改变c-Fos和c-Jun向雌激素反应性启动子的募集来调节ERα介导的转录激活。
Mol Endocrinol. 2006 Mar;20(3):534-43. doi: 10.1210/me.2005-0140. Epub 2005 Nov 17.
引用本文的文献
1
New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives.乳腺癌新一代雌激素受体靶向药物：现状与未来展望
Acta Mater Med. 2024 Feb 21;3(1):57-71. doi: 10.15212/amm-2024-0006. Epub 2024 Mar 15.
2
Different routes for the construction of biologically active diversely functionalized bicyclo[3.3.1]nonanes: an exploration of new perspectives for anticancer chemotherapeutics.构建具有生物活性的多种功能化双环[3.3.1]壬烷的不同途径：抗癌化疗新视角探索
RSC Adv. 2023 Jul 25;13(32):22389-22480. doi: 10.1039/d3ra02003g. eCollection 2023 Jul 19.
3
Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies.抗雌激素治疗耐药性的分子机制及新型靶向治疗
Cancers (Basel). 2022 Oct 24;14(21):5206. doi: 10.3390/cancers14215206.
4
Recent Advances in the Use of the Dimerization Strategy as a Means to Increase the Biological Potential of Natural or Synthetic Molecules.作为提高天然或合成分子生物学潜力手段的二聚化策略的最新进展。
Molecules. 2021 Apr 17;26(8):2340. doi: 10.3390/molecules26082340.
5
Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.用于治疗乳腺癌的选择性雌激素受体下调剂（SERDs）的最新进展。
RSC Med Chem. 2020 Mar 6;11(4):438-454. doi: 10.1039/c9md00570f. eCollection 2020 Apr 1.
6
Design of bivalent ligands targeting putative GPCR dimers.双价配体设计针对假定的 G 蛋白偶联受体二聚体。
Drug Discov Today. 2021 Jan;26(1):189-199. doi: 10.1016/j.drudis.2020.10.006. Epub 2020 Oct 16.
7
Synthesis and Characterization of Telmisartan-Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia.替米沙坦衍生的细胞死亡调节剂的合成与表征，以克服慢性髓性白血病中的伊马替尼耐药性
ChemMedChem. 2020 Jun 17;15(12):1067-1077. doi: 10.1002/cmdc.202000092. Epub 2020 May 6.
8
Estrogenic Activity of Coffee Constituents.咖啡成分的雌激素活性。
Nutrients. 2019 Jun 21;11(6):1401. doi: 10.3390/nu11061401.
9
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.抗雌激素药物联合免疫检查点抑制剂在乳腺癌免疫治疗中的应用。
J Steroid Biochem Mol Biol. 2019 Oct;193:105415. doi: 10.1016/j.jsbmb.2019.105415. Epub 2019 Jun 19.
10
ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.ZB716是一种甾体类选择性雌激素受体降解剂（SERD），在小鼠异种移植模型中口服给药可有效抑制肿瘤生长。
Oncotarget. 2018 Jan 8;9(6):6924-6937. doi: 10.18632/oncotarget.24023. eCollection 2018 Jan 23.
本文引用的文献
1
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer.雌激素受体通过远端增强子对乳腺癌中碳酸酐酶XII的调控
Cancer Res. 2008 May 1;68(9):3505-15. doi: 10.1158/0008-5472.CAN-07-6151.
2
Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.氟维司群：拓展激素受体阳性晚期乳腺癌患者的内分泌治疗选择
Breast. 2008 Apr;17 Suppl 3:S16-21. doi: 10.1016/j.breast.2007.12.004. Epub 2008 Mar 18.
3
Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.选择性雌激素受体下调剂之间功能上重要的机制差异的定义。
Cancer Res. 2007 Oct 1;67(19):9549-60. doi: 10.1158/0008-5472.CAN-07-1590.
4
Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents.Mdm2和应激诱导剂对雌激素受体α周转和反式激活的差异调节
Cancer Res. 2007 Jun 1;67(11):5513-21. doi: 10.1158/0008-5472.CAN-07-0967.
5
Raloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12.雷洛昔芬和ICI182,780通过激活功能2螺旋12中重叠的疏水氨基酸集增加雌激素受体α与核区室的结合。
Mol Endocrinol. 2007 Apr;21(4):797-816. doi: 10.1210/me.2006-0074. Epub 2007 Feb 13.
6
Characterization of molecular and structural determinants of selective estrogen receptor downregulators.选择性雌激素受体下调剂的分子和结构决定因素的表征
Breast Cancer Res Treat. 2007 May;103(1):37-44. doi: 10.1007/s10549-006-9353-2. Epub 2006 Oct 11.
7
Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter.雌激素占据的雌激素受体抑制细胞周期蛋白G2基因的表达，并在细胞周期蛋白G2启动子处募集一个阻遏复合物。
J Biol Chem. 2006 Jun 16;281(24):16272-8. doi: 10.1074/jbc.M513405200. Epub 2006 Apr 10.
8
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.氟维司群，晚期乳腺癌的一种新治疗选择：耐受性与现有药物对比
Ann Oncol. 2006 Feb;17(2):200-4. doi: 10.1093/annonc/mdj047. Epub 2005 Oct 26.
9
Identification of a novel, orally bioavailable estrogen receptor downregulator.一种新型口服生物可利用雌激素受体下调剂的鉴定。
Anticancer Drugs. 2005 Aug;16(7):751-6. doi: 10.1097/01.cad.0000171515.27439.de.
10
Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?乳腺癌中的内分泌学与激素疗法：用于乳腺癌的选择性雌激素受体调节剂和下调剂——它们是否已迷失方向？
Breast Cancer Res. 2005;7(3):119-30. doi: 10.1186/bcr1023. Epub 2005 Apr 6.
Zotero 插件